CD80 and neoplasm: The percentages of MHC-II and CD86 in tumor-bearing mice were significantly decreased at 1, 3, 5 and 7 weeks after LLC inoculation compared with Control (Figure 4), whereas the percentage of CD80 was not statistically different.